FDA approves Click’s digital therapeutic for episodic migraine
More than 37 million adults in the US are affected by migraine
Read More
Tag: Click Therapeutics
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
